Drug treatment and adherence of subjects <40 years with diagnosis of heterozygous familial hypercholesterolemia

Manuela Casula, Lorenza Scotti, Elena Tragni, Luca Merlino, Giovanni Corrao, Alberico L. Catapano

Research output: Contribution to journalArticle

Abstract

Background and aims We aimed at describing the therapeutic approach in young adult patients diagnosed with heterozygous familial hypercholesterolemia (HeFH) and their adherence and persistence to treatment. Methods From regional administrative databases, individuals aged ≤40 years, who received exemption for HeFH between January 1, 2003 and December 31, 2011, and concomitantly started statin treatment, were identified. Within the first year of treatment, we evaluated therapeutic changes, adherence as MPR (medication possession ratio), persistence as continuous drug coverage without gaps ≥60 days, and influencing factors using log binomial models. Results Of 1404 patients, 42.4% were initially treated with a high-efficacy statin. 23.4% of patients showed at least one treatment change. Mean MPR was 68.7% (29.9), and patients showing continued statin use were 47.0%. Therapy modification was significantly associated with a past cardiovascular event (relative risk, RR [95% confidential interval] 2.28 [1.69–3.09]) and at least one lipid test (RR 1.82 [1.31–2.53]). MPR ≥80% was significantly associated with the first statin prescribed (atorvastatin RR 1.28 [1.09–1.51] and rosuvastatin RR 1.21 [1.01–1.44], vs. simvastatin), a past cardiovascular event (RR 1.33 [1.12–1.59]), at least one therapy change (RR 1.28 [1.15–1.43]), at least a lipid test (RR 1.26 [1.07–1.49]). A similar pattern was observed for persistence. Conclusions This analysis of young adult HeFH patients showed that therapy change was quite frequent, and probably reflected adjustments according to individual response. Adherence and persistence were inadequate, even in this population at high cardiovascular risk, and they need to be improved through proper patient education and shared treatment decision-making approach.

Original languageEnglish
Pages (from-to)172-178
Number of pages7
JournalAtherosclerosis
Volume254
DOIs
Publication statusPublished - Nov 1 2016

Fingerprint

Hyperlipoproteinemia Type II
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pharmaceutical Preparations
Therapeutics
Young Adult
Lipids
Social Adjustment
Simvastatin
Medication Adherence
Statistical Models
Patient Education
Decision Making
Databases

Keywords

  • Adherence
  • Heterozygous familial hypercholesterolemia
  • Persistence
  • Statins
  • Treatment changes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Drug treatment and adherence of subjects <40 years with diagnosis of heterozygous familial hypercholesterolemia. / Casula, Manuela; Scotti, Lorenza; Tragni, Elena; Merlino, Luca; Corrao, Giovanni; Catapano, Alberico L.

In: Atherosclerosis, Vol. 254, 01.11.2016, p. 172-178.

Research output: Contribution to journalArticle

Casula, Manuela ; Scotti, Lorenza ; Tragni, Elena ; Merlino, Luca ; Corrao, Giovanni ; Catapano, Alberico L. / Drug treatment and adherence of subjects <40 years with diagnosis of heterozygous familial hypercholesterolemia. In: Atherosclerosis. 2016 ; Vol. 254. pp. 172-178.
@article{51ca6c86916c4af8bd62a9c96aa19b70,
title = "Drug treatment and adherence of subjects <40 years with diagnosis of heterozygous familial hypercholesterolemia",
abstract = "Background and aims We aimed at describing the therapeutic approach in young adult patients diagnosed with heterozygous familial hypercholesterolemia (HeFH) and their adherence and persistence to treatment. Methods From regional administrative databases, individuals aged ≤40 years, who received exemption for HeFH between January 1, 2003 and December 31, 2011, and concomitantly started statin treatment, were identified. Within the first year of treatment, we evaluated therapeutic changes, adherence as MPR (medication possession ratio), persistence as continuous drug coverage without gaps ≥60 days, and influencing factors using log binomial models. Results Of 1404 patients, 42.4{\%} were initially treated with a high-efficacy statin. 23.4{\%} of patients showed at least one treatment change. Mean MPR was 68.7{\%} (29.9), and patients showing continued statin use were 47.0{\%}. Therapy modification was significantly associated with a past cardiovascular event (relative risk, RR [95{\%} confidential interval] 2.28 [1.69–3.09]) and at least one lipid test (RR 1.82 [1.31–2.53]). MPR ≥80{\%} was significantly associated with the first statin prescribed (atorvastatin RR 1.28 [1.09–1.51] and rosuvastatin RR 1.21 [1.01–1.44], vs. simvastatin), a past cardiovascular event (RR 1.33 [1.12–1.59]), at least one therapy change (RR 1.28 [1.15–1.43]), at least a lipid test (RR 1.26 [1.07–1.49]). A similar pattern was observed for persistence. Conclusions This analysis of young adult HeFH patients showed that therapy change was quite frequent, and probably reflected adjustments according to individual response. Adherence and persistence were inadequate, even in this population at high cardiovascular risk, and they need to be improved through proper patient education and shared treatment decision-making approach.",
keywords = "Adherence, Heterozygous familial hypercholesterolemia, Persistence, Statins, Treatment changes",
author = "Manuela Casula and Lorenza Scotti and Elena Tragni and Luca Merlino and Giovanni Corrao and Catapano, {Alberico L.}",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.atherosclerosis.2016.10.020",
language = "English",
volume = "254",
pages = "172--178",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Drug treatment and adherence of subjects <40 years with diagnosis of heterozygous familial hypercholesterolemia

AU - Casula, Manuela

AU - Scotti, Lorenza

AU - Tragni, Elena

AU - Merlino, Luca

AU - Corrao, Giovanni

AU - Catapano, Alberico L.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Background and aims We aimed at describing the therapeutic approach in young adult patients diagnosed with heterozygous familial hypercholesterolemia (HeFH) and their adherence and persistence to treatment. Methods From regional administrative databases, individuals aged ≤40 years, who received exemption for HeFH between January 1, 2003 and December 31, 2011, and concomitantly started statin treatment, were identified. Within the first year of treatment, we evaluated therapeutic changes, adherence as MPR (medication possession ratio), persistence as continuous drug coverage without gaps ≥60 days, and influencing factors using log binomial models. Results Of 1404 patients, 42.4% were initially treated with a high-efficacy statin. 23.4% of patients showed at least one treatment change. Mean MPR was 68.7% (29.9), and patients showing continued statin use were 47.0%. Therapy modification was significantly associated with a past cardiovascular event (relative risk, RR [95% confidential interval] 2.28 [1.69–3.09]) and at least one lipid test (RR 1.82 [1.31–2.53]). MPR ≥80% was significantly associated with the first statin prescribed (atorvastatin RR 1.28 [1.09–1.51] and rosuvastatin RR 1.21 [1.01–1.44], vs. simvastatin), a past cardiovascular event (RR 1.33 [1.12–1.59]), at least one therapy change (RR 1.28 [1.15–1.43]), at least a lipid test (RR 1.26 [1.07–1.49]). A similar pattern was observed for persistence. Conclusions This analysis of young adult HeFH patients showed that therapy change was quite frequent, and probably reflected adjustments according to individual response. Adherence and persistence were inadequate, even in this population at high cardiovascular risk, and they need to be improved through proper patient education and shared treatment decision-making approach.

AB - Background and aims We aimed at describing the therapeutic approach in young adult patients diagnosed with heterozygous familial hypercholesterolemia (HeFH) and their adherence and persistence to treatment. Methods From regional administrative databases, individuals aged ≤40 years, who received exemption for HeFH between January 1, 2003 and December 31, 2011, and concomitantly started statin treatment, were identified. Within the first year of treatment, we evaluated therapeutic changes, adherence as MPR (medication possession ratio), persistence as continuous drug coverage without gaps ≥60 days, and influencing factors using log binomial models. Results Of 1404 patients, 42.4% were initially treated with a high-efficacy statin. 23.4% of patients showed at least one treatment change. Mean MPR was 68.7% (29.9), and patients showing continued statin use were 47.0%. Therapy modification was significantly associated with a past cardiovascular event (relative risk, RR [95% confidential interval] 2.28 [1.69–3.09]) and at least one lipid test (RR 1.82 [1.31–2.53]). MPR ≥80% was significantly associated with the first statin prescribed (atorvastatin RR 1.28 [1.09–1.51] and rosuvastatin RR 1.21 [1.01–1.44], vs. simvastatin), a past cardiovascular event (RR 1.33 [1.12–1.59]), at least one therapy change (RR 1.28 [1.15–1.43]), at least a lipid test (RR 1.26 [1.07–1.49]). A similar pattern was observed for persistence. Conclusions This analysis of young adult HeFH patients showed that therapy change was quite frequent, and probably reflected adjustments according to individual response. Adherence and persistence were inadequate, even in this population at high cardiovascular risk, and they need to be improved through proper patient education and shared treatment decision-making approach.

KW - Adherence

KW - Heterozygous familial hypercholesterolemia

KW - Persistence

KW - Statins

KW - Treatment changes

UR - http://www.scopus.com/inward/record.url?scp=84992126869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992126869&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2016.10.020

DO - 10.1016/j.atherosclerosis.2016.10.020

M3 - Article

AN - SCOPUS:84992126869

VL - 254

SP - 172

EP - 178

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

ER -